Cipla has received regulatory approval in India for MannKind’s Afrezza setting the stage for the debut of the inhaled insulin in a competitive market that has the second-highest burden of diabetes globally.
The duo’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?